CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Announces Presentations at Upcoming Medical Meetings
Details for the presentations are as follows:Prof. Robert Sutton to deliver plenary presentation on Phase 2b CARPO trial of Auxora in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting
羅伯特·薩頓教授將在2024年美國胰腺協會(APA)年會上就Auxora在急性胰腺炎(AP)中的20億CARPO試驗進行大會演講。
Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting
在2024年醫學緊急情況(EIM)會議上進行20億CARPO試驗的海報展示。
LA JOLLA, Calif., Nov. 20, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of an abstract for plenary presentation at the American Pancreatic Association (APA) 2024 Annual Meeting being held December 9-10 in Maui, HI, and the acceptance of an abstract for poster presentation at the Emergencies in Medicine (EIM) 2024 Meeting being held December 8-13 in Maui, HI.
加利福尼亞州拉荷亞，2024年11月20日 /PRNewswire/ -- 中國飛機租賃公司(CalciMedica) (納斯達克: CALC)，是一家專注於開發新型鈣釋放活化鈣(CRAC)通道抑制療法，治療急性和慢性炎症及免疫疾病的臨床階段生物醫藥公司，今天宣佈接受在美國胰腺協會(APA)2024年年會上的大會演講摘要，會議將於12月9日至10日在夏威夷毛伊島舉行，同時也接受在2024年醫學緊急情況(EIM)會議上的海報展示摘要，會議將在12月8日至13日在夏威夷毛伊島舉行。
Details for the presentations are as follows:
演講詳情如下:
Plenary Presentation at APA 2024 Annual Meeting
在APA 2024年年會的大會報告
Presentation Title: Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS
報告標題：Auxora減少急性胰腺炎和全身炎症反應綜合症(SIRS)患者嚴重臟器衰竭的發展
Presenter: Prof. Robert Sutton, B.A. (Hons), M.B., B.S., D.Phil., FRCS, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust
主講人：羅伯特·薩頓億曰.A.（榮譽）萬.b.億.S.、D.Phil.、FRCS，利物浦大學和利物浦大學醫院NHS基金會託管
Session Title: Abstract Session 2 – Pancreatitis
會議標題：摘要會議2 - 胰腺炎
Session Date and Time: Tuesday, December 10, 8:00-9:30 a.m. HST
會議日期和時間：2023年12月10日（星期二），上午8:00-9:30 HST
Poster Presentation at EIM 2024 Meeting
EIm 2024會議的海報展示
Presentation Title: A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS)- CARPO (NCT0468106)
報告標題：Auxora在急性胰腺炎（AP）患者及伴隨的全身性炎症反應綜合症（SIRS）中的隨機雙盲安慰劑對照劑量調整研究- CARPO (NCT0468106)
The presentation and poster will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at .
報告和海報將在會議後在CalciMedica的IR網站的醫療活動與報告部分提供。
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit .
CalciMedica是一家致力於開發新型CRAC通道抑制劑治療炎症和免疫疾病的臨床生物製藥公司。CalciMedica的專有技術針對CRAC通道的抑制作用可調節免疫反應，從而保護組織細胞，有潛力在當前沒有已批准療法的危及生命的炎症和免疫性疾病中提供治療效益。CalciMedica的主要產品候選藥物Auxora已經在多項完成的療效性臨床試驗中展現出積極和一致的臨床結果，對於第二期臨床試驗具有參考意義。奇泊 -NCT04681066）和冠狀病毒性肺炎患者的第2期臨床試驗（名爲CARDEA -NCT04345614）已經完成，繼續支持正在進行的第1/2AIPT研究（名爲CRSPA -NCT04195347），預計在2025年公佈數據，並已啓動其第2項研究（名爲KOURAGE -NCT06374797），預計在2025年公佈基於與AHRF相關的AKI的數據。 CalciMedica由來自Torrey Pines Therapeutics和哈佛CBR生物醫學研究所的科學家創立，總部位於加利福尼亞州拉荷亞。有關更多信息，請訪問。
CalciMedica是一家臨床階段的生物製藥公司，專注於開發用於治療炎症和免疫疾病的新型CRAC通道抑制劑療法。CalciMedica的專有技術針對CRAC通道的抑制，以調節免疫反應，保護組織細胞免受損傷，具有在目前尚無批准療法的危及生命的炎症和免疫疾病中提供治療益處的潛力。CalciMedica的主打產品Auxora在多個完成的有效性臨床試驗中顯示出積極且一致的臨床結果。CalciMedica已宣佈急性胰腺炎（AP）和伴有全身性炎症反應綜合症（SIRS）患者20億臨床試驗的頂線數據（稱爲CARPO – NCT04681066），並已完成針對COVID肺炎患者的Phase 2臨床試驗（稱爲CARDEA – NCT04345614）。該公司目前正在對伴隨急性缺氧呼吸衰竭（AHRF）的急性腎病（AKI）患者進行Phase 2臨床試驗（稱爲KOURAGE – NCT06374797），預計在2025年獲得數據，並繼續支持針對因天冬氨酸酶引起的胰腺毒性（AIPT）兒童患者的正在進行的Phase 1/2臨床試驗（稱爲CRSPA – NCT04195347），預計在2025年獲得數據。CalciMedica由來自Torrey Pines治療公司和哈佛CBR生物醫學研究所的科學家創立，總部位於加利福尼亞州拉荷亞。欲了解更多信息，請訪問。
Forward-Looking Statements
This communication contains forward-looking statements which include, but are not limited to, CalciMedica's ongoing and planned clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2b CARPO trial of Auxora for AP with accompanying SIRS, its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT, and its planned Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; and the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances. Risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2023, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law.
前瞻性聲明
本通訊包含前瞻性聲明，其中包括但不限於CalciMedica正在進行和計劃的臨床試驗及其時機、設計、預期患者招募情況以及這些試驗數據發佈的預期時間，包括其針對伴隨SIRS的AP的Phase 20億 CARPO試驗、正在進行的針對兒童AIPt患者的Phase 1/2 CRSPA試驗，以及計劃中的針對AKI和相關AHRF的Phase 2 KOURAGE試驗；Auxora在AP、AKI和AIPT治療中的潛在好處；以及CalciMedica專有科技在危及生命的炎症和免疫疾病中提供治療益處的潛力。這些前瞻性聲明遵循1995年《私人證券訴訟改革法》的安全港條款。CalciMedica對這些事項的預期和信念可能不會實現。實際結果和結果可能與這些前瞻性聲明中考慮的情況存在重大差異，這些差異可能是由不確定性、風險和情況變化引起的。可能導致實際結果與前瞻性聲明中考慮的情況存在重大差異的風險和不確定性已包含在CalciMedica截至2023年12月31日的年度報告的「風險因素」標題下，以及在CalciMedica隨後向SEC提交的10-k、10-Q或8-k表格的其他地方，這些文件可隨時在www.sec.gov上獲得。這些文件可以在CalciMedica的網頁ir.calcimedica.com/financials-filings/sec-filings上訪問。本聲明中的前瞻性陳述是在此日期作出的，CalciMedica沒有義務在此日期之後更新這些聲明，法律要求的除外。
CalciMedica Contact:
CalciMedica聯繫方式：Sarah Sutton / Kevin Murphy
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
[email protected]
(212) 600-1902
投資者和媒體
阿哥特合夥人。
來源：CalciMedica, Inc.
[email protected]
（212）600-1902
SOURCE CalciMedica, Inc.
源自CalciMedica，Inc。
